Analysts expect Cybin Inc. to report a consensus EPS loss of $1.04 on zero revenue, with the stock currently priced at $4.85 compared to a $49.05 average analyst target.
The key story for investors is the anticipated topline data readout from the Phase 2 trial of CYB004 for Generalized Anxiety Disorder (GAD).
As a clinical-stage biotech, Cybin's valuation depends heavily on clinical trial success and its cash runway, which is currently estimated to extend into late 2026. Recent progress includes the start of Phase 3 'EMBRACE' studies for its major depressive disorder candidate, CYB003, following previous FDA Breakthrough Therapy designation.